PROLONGATION OF PRIMATE CARDIAC ALLOGRAFT SURVIVAL BY TREATMENT WITH ANTI-CD40 LIGAND (CD154) ANTIBODY1

Abstract

Anti-CD154 antibody markedly prolongs the survival of cardiac allografts in primates and is well tolerated. Sustained dosing with hu5c8 yielded improved survival and may be associated with a lower incidence of vascular pathology. We conclude that hu5c8 therapy is an effective approach for inhibiting acute cardiac allograft rejection in primates.